Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Regeneron ( (REGN) ) has provided an update.
At the 2025 Annual Meeting of Shareholders held on June 13, Regeneron Pharmaceuticals’ shareholders voted on several key proposals. The election of Class I directors was confirmed, with nominees set to serve until the 2028 meeting. The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2025 was ratified. Additionally, an advisory vote approved the executive compensation package. A significant amendment to declassify the board of directors was passed, while proposals to eliminate supermajority vote requirements for certain amendments to the company’s Certificate of Incorporation were not approved.
The most recent analyst rating on (REGN) stock is a Hold with a $940.00 price target. To see the full list of analyst forecasts on Regeneron stock, see the REGN Stock Forecast page.
Spark’s Take on REGN Stock
According to Spark, TipRanks’ AI Analyst, REGN is a Neutral.
Regeneron’s overall stock score reflects strong financial performance and a reasonable valuation. However, bearish technical indicators and mixed earnings call results highlight challenges and uncertainties, balancing the positive financial aspects.
To see Spark’s full report on REGN stock, click here.
More about Regeneron
Regeneron Pharmaceuticals, Inc. is a biotechnology company that focuses on the discovery, development, and commercialization of medicines for serious diseases. The company operates in the pharmaceutical industry and is known for its innovative approach to drug development, targeting areas such as ophthalmology, oncology, and immunology.
Average Trading Volume: 1,334,973
Technical Sentiment Signal: Sell
Current Market Cap: $56.43B
Find detailed analytics on REGN stock on TipRanks’ Stock Analysis page.